Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents.
A series of novel benzimidazole derivatives were synthesized via parallel solution-phase chemistry. Many of these compounds were found to inhibit the growth of Staphylococcus aureus and Escherichia coli. Several analogues exhibited low micromolar minimal inhibitory concentrations (MIC) against both Gram-positive and Gram-negative bacteria of clinical relevance and could serve as leads for further optimizations for antibacterial research.
Ibis Therapeutics, a division of Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA. yhe@gnf.org
Yun
Y
He
Jun
J
Yang
Baogen
B
Wu
Lisa
L
Risen
Eric E
EE
Swayze
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D001562:Benzimidazoles / Q000138:chemical synthesis* / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data
D000900:Anti-Bacterial Agents; D001562:Benzimidazoles